Kura Oncology, Inc.
Clinical trials sponsored by Kura Oncology, Inc., explained in plain language.
Kura Oncology, Inc.
KURA
NASDAQ
Clinical-stage biopharmaceutical company focused on cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail takes aim at Hard-to-Treat leukemia Results expected Dec 2026 (estimated)
- New drug combo targets Hard-to-Treat cancers in early trial Results expected Jan 2027 (estimated)